Evofem Biosciences, Inc.
corporate_fare Company Profile
Evofem Biosciences, Inc. (OTC:EVFM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for EVFM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 10/10, with 11 rated 8 or above. Recent SEC coverage for EVFM spans 8-K, 10-Q, 10-K.
Recent high-impact activity:
- Evofem Executes 1-for-1,500 Reverse Split, Cutting Shares From 132.5M to ~88,353
- Evofem Q3 2026: $1.0M Quarterly Profit Masks Going-Concern Warning and Dec 1 Debt Wall
- Evofem Amends Adjuvant Notes: Full Repayment Due December 1, 2026
- Evofem Adds Second Phexx Manufacturing Source, Cutting Unit Costs 40%+
- Evofem Biosciences Reports $16.5M Loss, Warns of Going Concern Doubt
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 11,365 shares in EVFM as of the October 30, 2026 settlement, a 134.6% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 17, 2026, 70.9% of EVFM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.